Skip to main content

Table 1 Baseline demographics of the study population

From: A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity

 

Placebo

Pioglitazone

n

11

12

Female (%)

8 (72)

7 (52)

Age

41 ± 14.1

39.4 ± 10

Age asthma onset

21 ± 18.9

15 ± 11

Race

  

 Caucasian

9 (82)

8 (66.6)

 Black

2 (18)

4 (33.3)

BMI

43.5 ± 7.8

38.8 ± 6.8

Seasonal allergies (%)

10 (91)

10 (83)

GERD (%)

5 (45)

7 (58)

Depression (%)

6 (55)

7 (58)

Asthma exacerbation in last 12 months (%)

7 (64)

6 (50)

Oral steroids in last 12 months (%)

4 (36)

7 (58)

Inhaled corticosteroid n (%)

11 (100)

12 (100)

 High dose* (n)

5

4

 Medium dose (n)

4

8

 Low dose (n)

2

0

Long acting beta agonist, n (%)

9 (81.8)

10 (83.3)

Short acting beta agonist,n (%)

11 (100)

11 (92)

FeNO (ppb)

30.8 ± 28.4

27.6 ± 27.8

IgE (IU/ml)

575 ± 544.7

291.2 ± 313.2

Juniper Asthma Control

2.48 ± 1.30

1.75 ± 0.63

FEV1 (% pred pre BD)

81.5 ± 15.2

82.3 ± 12.1

FVC (% pred. pre BD)

85.3 ± 16.2

86.8 ± 13.7

FEV1/FVC (% pred. pre BD)

94.9 ± 7.67

95.3 ± 11.12

FEV1 (% pred. post BD)

88.1 ± 4.6

77.3 ± 25.1

FVC (% pred. post BD)

88.3 ± 16.3

79.5 ± 27.6

FEV1/FVC (% pred. post BD)

97.8 ± 7.82

90.9 ± 31.2

  1. *High, medium and low dose of ICS defined according to GINA guidelines [41]